Preclinical in vitro and in vivo screening assays for cancer preventive agent development
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261200433003C
- Awardee
-
IIT Research Institute UEI DGBUFQYMKWB5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,977,216
Award facts
- Opportunity
-
- N01CN2502676 Solicitation number
- Contract value 30% obligated
-
- $21,443,670.00 Current, with exercised options
- $23,349,236.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Chicago, IL 60616, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $425,100 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $1,047,642 | |
| Funding Only Action | $1,017,128 | |
| Supplemental Agreement for work within scope | $981,566 | |
| Funding Only Action | $924,000 | |
| Funding Only Action | $746,000 | |
| Funding Only Action | $870,568 | |
| Funding Only Action | $120,000 | |
| Original award | $845,212 |
Show all 12
About this award
This is a Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to the IIT Research Institute (IITRI), a non-profit contract research organization. The $23,349,236 contract is for the provision of preclinical in vitro and in vivo screening assays to support the development of cancer preventive agents. IITRI, which has extensive experience supporting the preclinical development of various therapeutics for federal agencies, will leverage its expertise in non-GLP and GLP studies, analytical assay development, and process validation to advance promising cancer prevention therapies. This contract is not associated with any set-aside designation. In addition to this award, IITRI holds several significant indefinite delivery/indefinite quantity (IDIQ) contract vehicles with agencies like the National Institute of Allergy and Infectious Diseases, the National Center for Advancing Translational Sciences, and the National Institute of Neurological Disorders and Stroke, enabling efficient access to IITRI's comprehensive preclinical research capabilities.
Quick answers
Who was awarded contract HHSN261200433003C?
HHSN261200433003C was awarded to IIT Research Institute by National Cancer Institute (National Institutes of Health) on April 30, 2004.
How much is contract HHSN261200433003C worth?
The government has obligated $6,977,216 on HHSN261200433003C. Its current value, with exercised options, is $21,443,670. Its potential value, with all options, is $23,349,236.
Was contract HHSN261200433003C competed?
The extent of competition for HHSN261200433003C was full and open competition. The government received 6 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award